Assembly Biosciences, Inc.
http://www.assemblybio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Assembly Biosciences, Inc.
Assembly Looks To Quickly Move Past ABI-H2158 Discontinuation
The company’s triple-combination studies with vebicorvir and next-generation core inhibitor programs may hold more promise in hepatitis B.
Deal Watch: Lilly Finds New Partners For Genetic Disorders, Protein Degradation
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
Assembly Falls Well Short In Attempt At Finite HBV Therapy
Biotech tried to show that a core inhibitor combined with standard hepatitis B therapy could yield lasting benefit after treatment. Vebicorvir will continue to be studied as a chronic treatment in HBV.
Asia Deal Watch: Promethera Calls On Hao Tian For Asian JV To Advance Its Liver Candidates
Plus recent deals involving BeiGene, Assembly Biosciences, Piramal, Medivant, Revitope, Junshi, JW Therapeutics, Eureka, Acepodia, Chiesi, Bayer, NewG Lab, AnHeart
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Assembly Pharmaceuticals
- Ventrus Biosciences, Inc.